Modifying Post-Transplant Cyclophosphamide Platform to Improve Safety in HLA-Matched Allogeneic HCT: A Reduced Dose Plus Adjunctive Strategies. (PubMed, Transplant Cell Ther) - Oct 21, 2025 - "In November 2021, we implemented a modified platform using reduced-dose PTCY (40 mg/kg; PTCY40) with tacrolimus, plus G-CSF from day +7 and letermovir for CMV-positive patients. Non-relapse mortality was significantly lower with PTCY40 (0% vs. 8.6%, p=0.032), with similar overall survival (78.2% vs. 81.1%, p=0.941) and relapse incidence (25.1% vs. 24.1%, p=0.772). These findings support the safety of this modified GVHD prophylaxis approach."
Journal • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation • CD4
|
|
Alexandra Pedraza; Blanca De Moner; Carmen Martinez; Enric Carreras; Enric Cascos; Esther Carcelero; Filipe R Pinto; Francesc Fernández-Avilés; Joan Cid; Jordi Esteve; Julia Martinez-Sanchez; Laia Guardia; Laura Rosiñol; Maria Queralt Salas; Maria Suárez-Lledó; Maribel Diaz-Ricart; Miquel Lozano; Montserrat Rovira; Paola Charry
|